Peptides Codex
ENFR
← Home
Ghrelin receptor agonist (synthetic peptide analog)

Relamorelin

Relamorelin is a synthetic, centrally penetrant agonist of the ghrelin/growth hormone secretagogue receptor developed as a prokinetic. It has been investigated in clinical trials for diabetic gastroparesis and chronic constipation and is not an approved medicine authorized by Health Canada. This page is educational and is not medical advice.

By The Peptides Codex Editorial TeamReviewed July 10, 2026
Length
n/a
Class
Ghrelin receptor agonist (synthetic peptide analog)
Function
Growth hormone secretagogue receptor agonist and prokinetic
Context
Investigational for diabetic gastroparesis and related motility disorders; not an approved medicine and not authorized by Health Canada

A ghrelin analog studied for gut motility rather than growth hormone effects.

Also known as: RM-131 · BIM-28131 · ghrelin receptor agonist

Part of the Growth hormone & IGF peptides cluster

Overview

Relamorelin is a synthetic, centrally penetrant agonist of the ghrelin/growth hormone secretagogue receptor developed as a prokinetic. It has been investigated in clinical trials for diabetic gastroparesis and chronic constipation and is not an approved medicine authorized by Health Canada. This page is educational and is not medical advice.

Source & context

Biological / chemical source: Synthetic peptide analog of ghrelin

Primary research or clinical context: Investigational for diabetic gastroparesis and related motility disorders; not an approved medicine and not authorized by Health Canada

Motility angle

Ghrelin accelerates gastric emptying, and relamorelin was designed to harness that prokinetic effect. This positions it differently from GH-focused secretagogues, even though it acts at the same receptor family.

Development status

Relamorelin has been studied in phase II trials for gastroparesis and related conditions, but its development path has been uncertain and it remains investigational. Availability and approval status may change over time and differ by country.

FAQ about Relamorelin

What is Relamorelin?+

Relamorelin is a synthetic, centrally penetrant agonist of the ghrelin/growth hormone secretagogue receptor developed as a prokinetic. It has been investigated in clinical trials for diabetic gastroparesis and chronic constipation and is not an approved medicine authorized by Health Canada. This page is educational and is not medical advice.

Is Relamorelin an approved medicine?+

Relamorelin is discussed here as a research / educational topic. Investigational for diabetic gastroparesis and related motility disorders; not an approved medicine and not authorized by Health Canada. This is not medical advice.

What is the typical length of Relamorelin?+

Relamorelin is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.

Related peptides

PE-22-28
Research peptide
PE-22-28 is a synthetic heptapeptide derived from spadin, developed as a shortened analog that inhibits the TREK-1 potassium channel. It has been examined in rodent neuroscience studies and is not authorized as a medicine by Health Canada.
Cortexin
Polypeptide complex
Cortexin is a low-molecular-weight polypeptide complex extracted from cerebral cortex tissue, studied largely in Russian neuroscience literature. It is marketed as a drug in some countries but is not authorized by Health Canada.
Pinealon
Research peptide
Pinealon is a synthetic tripeptide (Glu-Asp-Arg, EDR) from the Khavinson short-peptide bioregulator class. It has been studied for proposed neuroprotective and gene-regulatory effects in mostly Russian laboratory research and is not authorized as a medicine by Health Canada.
Teverelix
GnRH antagonist (decapeptide analog)
Teverelix is a synthetic decapeptide GnRH antagonist that binds competitively and reversibly to pituitary GnRH receptors, suppressing luteinizing hormone and follicle-stimulating hormone. It is an investigational compound studied in prostate disorders and is not authorized by Health Canada. This page is educational and is not medical advice.

References & further reading

  1. 1.Wikipedia — Relamorelin
  2. 2.PubChem — compound summary for Relamorelin (CID 85364156)
Disclaimer: Educational content only. Not medical advice. Not instructions for human use. Research peptides and unapproved products may be restricted or illegal to market for human consumption in your jurisdiction. Consult qualified professionals and applicable law.
You might also like: All peptides · Atlas · Research · Tools
Cite this: Peptides Codex — Relamorelin educational profile.
Tip: Use browser print (Ctrl/Cmd + P) for a clean PDF of this page.